Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 87Carcinoma, Non-Small-Cell Lung 76Breast Neoplasms 73Recurrence 64Colorectal Neoplasms 63Pancreatic Neoplasms 60Melanoma 58Advanced Solid Tumor 57Carcinoma, Hepatocellular 56Multiple Myeloma 55Lymphoma 53Leukemia, Myeloid, Acute 53Advanced Solid Tumors 53Neoplasm Metastasis 50Stomach Neoplasms 47Precursor Cell Lymphoblastic Leukemia-Lymphoma 44Lymphoma, B-Cell 40Solid Tumor 39Ovarian Neoplasms 38Lymphoma, Non-Hodgkin 38Lung Neoplasms 36Glioblastoma 35Prostatic Neoplasms 34Leukemia 28Head and Neck Neoplasms 27Leukemia, Lymphocytic, Chronic, B-Cell 26Uterine Cervical Neoplasms 25Burkitt Lymphoma 24Esophageal Neoplasms 23Urinary Bladder Neoplasms 20

Interventions

Denosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Unknown × Bone Metastasis From Solid Tumors × Clear all
NCT04494373 2020-08-04

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Unknown
154 enrolled
Other solid neoplasm

Bone Metastasis From Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡